ArticleScientific reports2025
Midodrine and clinical outcomes in patients on maintenance hemodialysis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ten tips to reduce fracture risk by non-pharmacologic interventions in CKD-associated osteoporosis.Clinical kidney journal · 2026Review
- Effects of microplastics and nanoplastics on the kidneys.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Patients on hemodialysis often experience intradialytic hypotension (IDH), contributing to increased cardiovascular disease and mortality. Midodrine, an α-1 adrenergic receptor agonist, is commonly prescribed for IDH treatment or prevention. However, the effects of midodrine on clinical outcomes remain unclear. We aimed to evaluate the impact of midodrine use on clinical outcomes in patients on maintenance hemodialysis. This retrospective study evaluated patients according to midodrine prescriptions based on a dataset from the hemodialysis quality assessment program and Health Insurance Review and Assessment. Propensity score matching was employed to minimize bias in baseline characteristics. The Cox regression model was used to estimate the hazard ratio (HR) and confidence interval (CI) for all-cause mortality and cardiovascular events (CVEs). Approximately 9.6% of 71,540 patients were prescribed midodrine. The numbers of patients in the No-proscription and Midodrine groups were 20,305 and 6,887 after matching, respectively. The 5-year patient survival rates in the No-prescription and Midodrine groups were 62.6% and 58.0%, respectively (P < 0.001). Midodrine use was associated with an increased risk of all-cause mortality (adjusted HR: 1.17, 95% CI 1.13-1.22, P < 0.001). A high dose of midodrine was associated with a higher HR for mortality than that in a No-prescription or low dose of midodrine. The risk of CVE between the groups was not significantly different. This study showed that midodrine use was associated with a dose-dependent increase in all-cause mortality. Clinicians should actively search for and treat comorbidities and risk factors for IDH in patients requiring midodrine, especially frequent dosing. The findings should be interpreted with caution due to the observational nature of the study and should be validated in future prospective studies incorporating comprehensive IDH data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.